子宫腺肌症患者血清MMP2/9的相关性及PVA联合重组人血管内皮抑素介入治疗的机制分析

Involvement of MMP2/9 in the pathogenesis of uterine adenomyosis and mechanisms of PVA combined recombinant human endostatin

目的:本研究对血清MMP2/9与子宫腺肌症的相关性进行分析,并探讨宫动脉栓塞术(PVA)联合重组人血管内皮抑素介入治疗的相关机制。方法:选择本院经彩色多普勒检查确诊为子宫腺肌症的80例患者进行分析,比较子宫腺肌症患者与对照组血清基质金属蛋白酶-2(MMP-2)及基质金属蛋白酶-9(MMP-9)水平的差异性。80例患者随机分为两组:重组人血管内皮抑素组和PVA联合重组人血管内皮抑素组。重组人血管内皮抑素组给予重组人血管内皮抑素介入治疗,PVA联合重组人血管内皮抑素组患者进行PVA联合重组人血管内皮抑素介入治疗。比较两组治疗后的痛经程度、月经量、子宫体积以及血清中MMP-2及MMP-9水平的变化。结果:PVA联合重组人血管内皮抑素组患者的痛经程度、月经量及子宫体积改善程度优于重组人血管内皮抑素组,且两组血清中MMP-2及MMP-9水平较治疗前均有明显的改善,但仍高于对照组。结论:PVA联合重组人血管内皮抑素介入治疗子宫腺肌症主要通过抑制血清中MMP-2及MMP-9水平发挥作用。

Objective： The present research aimed to explore the involvement of MMP2/9 in the pathogenesis of uterine adenomyosis and mechanisms of PVA combined recombinant human endostatin. Methods： 80 cases of uterine denomyosis pa- tients were divided into 2 groups, recombinant human endostatin （RHD） group and PVA combined RHD group. The degree of dysmenorrhea, menstrual blood volume and uterine size were analyzed in each group. The content of MMP2 and MMP9 in each group was also be detected. The aforementioned parameters were also assayed before drug treatment in uterine adenomysis pa- tients. Results： PVA combined RHD normalized the affected dysmenorrhea, menstrual blood volume and uterine size as well as up-regulated MMP2 and MMP9 greatly with a statistical difference. Conclusion： PVA combined RHD remedy uterine adeno- mysis by inhibiting aberrant MMP9 and MMP9.